Opioid use and abuse is a significant social, health and economic issue in Canada. Researchers at the University of Calgary’s Faculty of Veterinary Medicine (UCVM) and Hotchkiss Brain Institute (HBI) at the Cumming School of Medicine (CSM) have discovered that an existing anti-gout medication is effective in reducing the severity of withdrawal symptoms in opioid-dependent rodents.
Opioids are the mainstay of treatment strategies to reduce pain, but withdrawal can be a serious problem when patients stop taking these drugs. However, beyond the recognition that microglia play a role in this phenomenon, little is known about the cellular mechanisms involved. Now, new research shows how microglia contribute to withdrawal in rodents and identifies a potential path toward easing withdrawal in patients.
Drug eases withdrawal symptoms in rodents, human trials next Originally published by CBC News on January 30, 2017 University of Calgary researchers believe a medication already being used to treat gout could be a weapon in the fight against opioid dependency — by alleviating withdrawal symptoms. “It’s quite effective [on Read more…
The Canadian Association for Neuroscience (CAN) is proud to announce that Tuan Trang, from the Hotchkiss Brain Institute at the University of Calgary, will receive a 2017 CAN Young Investigator Award at the upcoming 11th Annual Canadian Neuroscience Meeting in Montréal, on May 30th 2017.